Shares of Inari Medical, Inc. (NASDAQ: NARI) surged 7.85% in after-hours trading on October 28, 2024, after the medical device company reported strong third-quarter results and raised its full-year revenue guidance.
For the third quarter ended September 30, 2024, Inari Medical posted revenue of $153.4 million, up 21.4% year-over-year, surpassing analysts' expectations of $150.7 million. The company attributed the growth to an expansion in its sales territories, opening of new accounts, increased adoption of its procedures, global commercial expansion, and the introduction of new products.
While Inari Medical reported a GAAP operating loss of $13.6 million, its non-GAAP operating loss improved sequentially to $0.4 million, compared to a non-GAAP operating income of $4.8 million in the same period last year. The company expects to achieve sustained operating profitability in the first half of 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.